RecruitingNCT07247968
Esketamine with electroconvulsive therapy for severe depression in adolescents
About this title
Read the official source — NCT07247968Medication studyAges 13–17China
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 13 years to 17 years. Other eligibility criteria apply.
- Listed locations
- Chongqing and 1 more locationSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 25, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 220
- Sponsor
- Min Su
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- China
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT07247968
- Official title
Show the full official title
Clinical and Mechanistic Study of Subanesthetic-dose Esketamine in Modified Electroconvulsive Therapy for Adolescents With Severe Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Chongqing
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Min Su.
Does this study involve medication?
Yes. The study involves medication, including Esketamine injection group (0.25 mg/kg).
Who can participate?
This study is for people with depression. Listed age limits: 13 years to 17 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
